Piotr Olejnik
Overview
Explore the profile of Piotr Olejnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olejnik P, Golenia A, Malyszko J
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004055
As the world's population continues to age, social patterns are changing, making aging a notable public health challenge. With aging as the major risk factor for cognitive decline, the global...
2.
Olejnik P, Golenia A
Cells
. 2024 Dec;
13(23).
PMID: 39682711
Cognitive impairment is a major healthcare challenge worldwide, with vascular cognitive impairment (VCI) being its second leading cause after Alzheimer's disease. VCI is a heterogeneous group of cognitive disorders resulting...
3.
Golenia A, Olejnik P, Maciejewska O, Wojtaszek E, Zebrowski P, Malyszko J
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458033
Chronic kidney disease (CKD) is a risk factor for cognitive impairment (CI), and this risk is the highest in patients with end-stage kidney disease (ESKD). As a multifactorial disease, CI...
4.
Olejnik P, Roszkowska Z, Adamus S, Kasarello K
Pharmacol Rep
. 2024 Aug;
76(5):926-943.
PMID: 39177889
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by pathological processes of demyelination, subsequent axonal loss, and neurodegeneration within the central nervous system. Despite the availability of numerous disease-modifying...
5.
Golenia A, Olejnik P, Grusiecka-Stanczyk M, Zolek N, Wojtaszek E, Zebrowski P, et al.
Brain Behav
. 2024 Aug;
14(8):e3647.
PMID: 39135287
Introduction: Cognitive impairment (CI) is common in both end-stage kidney disease (ESKD) and alcohol-related liver cirrhosis. The aim of this study was to assess the prevalence and patterns of CI...
6.
Olejnik P, Buczma K, Cudnoch-Jedrzejewska A, Kasarello K
Immunol Res
. 2024 Mar;
72(4):554-565.
PMID: 38446328
Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination and damage to the central nervous system. It is well known, the significance of the involvement and influence...
7.
Olejnik P, Golenia A, Maciejewska O, Wojtaszek E, Zebrowski P, Malyszko J
Ren Fail
. 2024 Jan;
46(1):2306232.
PMID: 38275184
Aim Of The Study: The study aimed to assess the prevalence of executive function impairment among patients with chronic kidney disease (CKD) undergoing dialysis, with no subjective cognitive problems and...
8.
Grel H, Woznica D, Ratajczak K, Kalwarczyk E, Anchimowicz J, Switlik W, et al.
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37685840
Neurodegenerative diseases (NDs) are a diverse group of disorders characterized by the progressive degeneration and death of neurons, leading to a range of neurological symptoms. Despite the heterogeneity of these...
9.
Ratajczak K, Grel H, Olejnik P, Jakiela S, Stobiecka M
Biosens Bioelectron
. 2023 Sep;
240:115644.
PMID: 37660460
Recent technological advancements in testing and monitoring instrumentation have greatly contributed to the progress in cancer treatment by surgical, chemotherapeutic and radiotherapeutic interventions. However, the mortality rate still remains high,...
10.
Golenia A, Olejnik P, Zolek N, Wojtaszek E, Malyszko J
Kidney Blood Press Res
. 2023 Aug;
48(1):587-595.
PMID: 37619550
Introduction: Cognitive impairment (CI) is common in end-stage kidney disease (ESKD), including kidney transplant recipients. Patients with cognitive problems may find it difficult to comply with medical recommendations after kidney...